In vitro activities of azithromycin, clarithromycin, L-ofloxacin, and other antibiotics against Chlamydia pneumoniae.
dc.contributor.author | Hammerschlag, M R | |
dc.contributor.author | Qumei, K K | |
dc.contributor.author | Roblin, P M | |
dc.date.accessioned | 2023-06-29T15:41:26Z | |
dc.date.available | 2023-06-29T15:41:26Z | |
dc.date.issued | 1992-07 | |
dc.identifier.citation | Hammerschlag MR, Qumei KK, Roblin PM. In vitro activities of azithromycin, clarithromycin, L-ofloxacin, and other antibiotics against Chlamydia pneumoniae. Antimicrob Agents Chemother. 1992 Jul;36(7):1573-4. doi: 10.1128/AAC.36.7.1573. PMID: 1324650; PMCID: PMC191624. | en_US |
dc.identifier.issn | 0066-4804 | |
dc.identifier.pmid | 1324650 | |
dc.identifier.uri | http://hdl.handle.net/20.500.12648/10329 | |
dc.description.abstract | The in vitro susceptibilities of 11 strains of Chlamydia pneumoniae to azithromycin, clarithromycin, erythromycin, L-oflaxacin, and doxycycline were determined. Clarithromycin was the most active agent tested, with an MIC for 90% of strains and minimal chlamydiacidal concentration for 90% of strains of 0.03 microns/ml. The activity of azithromycin was similar to those of erythromycin and doxycycline, with MICs for 90% of strains of 0.125 to 0.25 microns/ml. However, the prolonged half-life and enhanced tissue penetration of azithromycin should allow for less frequent dosing and shorter duration of therapy than with erythromycin or clarithromycin. L-Ofloxacin had activity similar to that of ofloxacin, with MICs of 0.125 to 0.5 micron/ml. From the results of this in vitro study, azithromycin and clarithromycin appear to be effective antibiotics that may have a role in the treatment of infections due to C. pneumoniae. | |
dc.language.iso | en | en_US |
dc.relation.url | https://journals.asm.org/doi/epdf/10.1128/aac.36.7.1573 | en_US |
dc.rights | Attribution-NonCommercial-NoDerivatives 4.0 International | * |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/4.0/ | * |
dc.title | In vitro activities of azithromycin, clarithromycin, L-ofloxacin, and other antibiotics against Chlamydia pneumoniae. | en_US |
dc.type | Article/Review | en_US |
dc.source.journaltitle | Antimicrobial agents and chemotherapy | en_US |
dc.source.volume | 36 | |
dc.source.issue | 7 | |
dc.source.beginpage | 1573 | |
dc.source.endpage | 4 | |
dc.source.country | United States | |
dc.description.version | VoR | en_US |
refterms.dateFOA | 2023-06-29T15:41:28Z | |
html.description.abstract | The in vitro susceptibilities of 11 strains of Chlamydia pneumoniae to azithromycin, clarithromycin, erythromycin, L-oflaxacin, and doxycycline were determined. Clarithromycin was the most active agent tested, with an MIC for 90% of strains and minimal chlamydiacidal concentration for 90% of strains of 0.03 microns/ml. The activity of azithromycin was similar to those of erythromycin and doxycycline, with MICs for 90% of strains of 0.125 to 0.25 microns/ml. However, the prolonged half-life and enhanced tissue penetration of azithromycin should allow for less frequent dosing and shorter duration of therapy than with erythromycin or clarithromycin. L-Ofloxacin had activity similar to that of ofloxacin, with MICs of 0.125 to 0.5 micron/ml. From the results of this in vitro study, azithromycin and clarithromycin appear to be effective antibiotics that may have a role in the treatment of infections due to C. pneumoniae. | |
dc.description.institution | SUNY Downstate | en_US |
dc.description.department | Pediatrics | en_US |
dc.description.degreelevel | N/A | en_US |
dc.identifier.journal | Antimicrobial agents and chemotherapy | |
dc.identifier.issue | 7 | en_US |